James M. Roach

James M. Roach

Hoofd Techniek/Wetenschap/O&O bij CLEMENTIA PHARMACEUTICALS INC
66 jaar
Health Technology
Consumer Services

Profiel

James M.
Roach
currently works at Clementia Pharmaceuticals, Inc., as Executive Vice-President-Research & Development.
Dr. Roach also formerly worked at Sumitomo Pharma America, Inc., as Senior Vice President-Medical Affairs from 2002 to 2008, Millennium Pharmaceuticals, Inc., as Head-Medical Affairs & Clinical Research, LeukoSite, Inc., as Head-Medical Affairs, Momenta Pharmaceuticals, Inc., as Chief Medical Officer & Senior VP-Development from 2011 to 2016, Astra USA, Inc., as Head-Medical Affairs, Harvard Medical School, as Assistant Clinical Professor, Veristat LLC, as Chief Medical Officer, and Pulmatrix, Inc., as Chief Medical Officer from 2017 to 2019.
Dr. Roach received his undergraduate degree from College of the Holy Cross (Massachusetts) and doctorate degree from Georgetown University School of Medicine.

Actieve functies van James M. Roach

BedrijvenFunctieBegin
CLEMENTIA PHARMACEUTICALS INC Hoofd Techniek/Wetenschap/O&O -

Eerdere bekende functies van James M. Roach

BedrijvenFunctieEinde
PULMATRIX, INC. Hoofd Techniek/Wetenschap/O&O 08-03-2019
MOMENTA PHARMACEUTICALS, INC. Hoofd Techniek/Wetenschap/O&O 29-11-2016
Hoofd Techniek/Wetenschap/O&O 01-02-2008
Astra USA, Inc.
Hoofd Techniek/Wetenschap/O&O -
Hoofd Techniek/Wetenschap/O&O -
Ervaring van James M. Roach in detail bekijken

Opleiding van James M. Roach

Ervaring
Beklede functies

Actief

Inactief

Beursgenoteerde bedrijven

Bedrijven in privébezit

Connecties

53

Eerstegraads connecties

11

Bedrijven verbonden in de eerste graad

Man

Vrouw

Besturend

Uitvoerend

Verwante bedrijven

Bedrijven in privébezit11

Health Technology

Health Technology

Health Technology

Health Technology

Consumer Services

Astra USA, Inc.

Consumer Services

Health Technology

Consumer Services

Health Technology

Health Technology

  1. Beurs
  2. Insiders
  3. James M. Roach
DE LAATSTE UREN | -40 %: De beste tools voorbehouden aan abonnees om de beste beleggingen van morgen te identificeren!
d
:
:
PROFITEER NU